Expression of serum FSTL-1 in bone metastasis of prostate cancer and its clinical implication
DING Tao
HE Xiao-zhou
XU Xian-lin
XU Hai-yan
ZHOU Cui-xing
WANG Yu-ji
Abstract：Objective:To investigate the expression of follistatin-like protein 1 (FSTL-1) in bone metastasis of prostate cancer (BMPC),the correlation of serum FSTL-1 with the chronic inflammatory factor interleukin-6 (IL-6) and bone morphogenetic protein 6(BMP6),and the clinical application value of serum FSTL-1 in BMPC.Methods:Using ELISA,we measured the expression levels of serum FSTL-1,IL-6,and BMP6 in 35 patients with BMPC and another 30 with benign prostatic hyperplasia (BPH) and performed correlation analysis on the data obtained.Results:Compared with the BPH controls,the BMPC patients showed a significantly decreased expression of serum FSTL-1 ([34.45 ± 12.35] μg/L vs [20.23 ± 8.69] μg/L,P ＜ 0.01) and increased levels of IL-6([11.21 ±8.62] μg/L vs [23.56 ±20.12] μg/L,P ＜0.05) and BMP6 ([293.50 ±39.72] μg/L vs [428.30 ± 178.40] μg/L,P ＜ 0.05).There was a significant negative correlation between the level of serum FSTL-1 and those of IL-6 and BMP6 in the BMPC patients,with correlation coefficients of-0.971 and-0.972,respectively (P ＜ 0.05).Conclusion:The expression of serum FSTL-1 decreases in patients with bone metastasis of prostate cancer,and it is correlated with the levels of inflammatory factor and cell transformation factor.This finding offers a novel biological marker for the development and progression of prostate cancer as well as a new biological target factor for its intervention.
Keywords：prostate cancerbone metastatsisfollistatin-like protein 1interleukin-6bone morphogenetic protein 6
Publication Date：2014-11-16
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)